Skip to search formSkip to main contentSkip to account menu

Vistusertib

Known as: Benzamide, 3-(2,4-Bis((3S)-3-methyl-4-morpholinyl)pyrido(2,3-d)pyrimidin-7-yl)-N-methyl- 
An orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Vistusertib inhibits the… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

AZD2014
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study
The PI3K/AKT/mTOR pathway activation plays a central role in glioblastoma multiforme (GBM) development and progression, and in… 
2019
2019
OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel+/- novel agents in platinum-resistant ovarian cancer: Vistusertib
Abstract Background OCTOPUS, an NCRI investigator-initiated umbrella phase II trial, tests the addition of targeted agents to… 
2019
2019
Phase I study of orally administered 14Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics in…
PurposeVistusertib is an orally bioavailable dual target of rapamycin complex (TORC) 1/2 kinase inhibitor currently under… 
2019
2019
Vistusertib for ER-Positive Breast Cancer
The PI3K-AKT-mTOR pathway is the subject of intense clinical investigation, particularly in ER-positive breast cancer. Mutations… 
2018
2018
Selumetinib-based therapy in uveal melanoma patient-derived xenografts
The prognosis of metastatic uveal melanoma (UM) is among the worst of all human cancers. The identification of near-ubiquitous… 
2017
2017
A study of vistusertib in combination with selumetinib in patients with advanced cancers: TORCMEK phase Ib results.
2548Background: PI3K/mTOR and MAPK pathways are aberrantly activated in many tumours and interact to promote tumour growth and… 
2017
2017
OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel+/- novel agents in platinum-resistant ovarian cancer—Vistusertib (AZD2014).
TPS5609Background: There is an urgent need to improve outcomes for patients with platinum-resistant and refractory ovarian cancer… 
Review
2017
Review
2017
Abstract CT004: European pediatric precision medicine program in recurrent tumors: first results from MAPPYACTS molecular profiling trial towards AcSe-ESMART proof-of-concept study
In the area of precision medicine we initiated the multi-centric, international trials MAPPYACTS ‘A multicentric, prospective… 
2017
2017
VIKTORY trial: Report on AZD1775/paclitaxel in TP53 mutation (+) GC, selumetinib/paclitaxel in ras aberrant GC, AZD5363/paclitaxel in PIK3CA mt and biomarker negative, savolitinib/docetaxel in met…
4024Background: The VIKTORY trial is a biomarker-based umbrella trial in GC. Methods: See table below. Results: From June 2014 to… 
2017
2017
CANCAP02: A study into the pharmacodynamic biomarker effects of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (RP).
97Background: Additional systemic therapy given to unselected patients (pts) around RP has yet to improved pt survival. Further… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)